Circulating IGFBP-2: a novel biomarker for incident dementia.
Emer R McGrathJayandra J HimaliDaniel LevySarah C ConnerCharles S DeCarliMatthew P PasePaul CourchesneClaudia L SatizabalRamachandran S VasanAlexa S BeiserSudha SeshadriPublished in: Annals of clinical and translational neurology (2019)
Elevated circulating IGFBP-2 levels were associated with an increased risk of both all-cause dementia and Alzheimer's disease. Addition of IGFBP2 plasma levels to a model of traditional risk factors significantly improved dementia risk classification. Manipulation of insulin-like growth factor signaling via IGFBP-2 may be a promising therapeutic target for dementia.